- Startseite
- 4-6
- Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis - The
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis - The
4.8 (629) · € 19.00 · Auf Lager
AGO Algorithms for the Treatment of Breast Cancer: Update 2021. - Abstract - Europe PMC
Outcomes of Older Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2 -negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis - The Lancet Oncology
Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approach - ScienceDirect
Cancers, Free Full-Text
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2 -negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis - The Lancet Oncology
Cancers, Free Full-Text
Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study
Metastatic Breast Cancer
Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer
Determinants of response to CDK4/6 inhibitors in the real-world setting
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future - The Lancet
Resistance to CDK4/6 inhibition: Mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancer - ScienceDirect
